Taxol Chemotherapy
Links shared publicly online about this topic
Taxol Boosts Odds of Chronic Pain:
health.msn.com — “Taxol Boosts Odds of Chronic Pain:” View full resource at health.msn.com
Most Recently Shared on November 30, 2009 at 11:24 pm By:
Taxol Boosts Odds of Chronic Pain: http://bit.ly/5nJLDv
Taxol Boosts Odds of Chronic Pain - US News and World Report
health.usnews.com — “ MONDAY, Nov. 30 (HealthDay News) -- The chemotherapy drug paclitaxel (Taxol) increases the risk of chronic neuropathic pain in breast cancer survivors, a new study shows. It included 240 women who took part in clinical trials of Taxol between 1994 and 2001. Those who experienced chemotherapy-induced peripheral neuropathy during their treatment with Taxol were three times more likely to eventually be diagnosed with chronic neuropathic pain. ” View full resource at health.usnews.com
Most Recently Shared on December 1, 2009 at 3:25 am By:
Timothy Lomauro Doctor, Psychologist, and PhD
"Taxol Boosts Odds of Chronic Pain - Breast cancer patients getting the drug may suffer long-term neuropathic ..." http://hub.tm/?qtKHL
Taxol Boosts Odds of Chronic Pain - Drugs.com MedNews
drugs.com — “The chemotherapy drug paclitaxel (Taxol) increases the risk of chronic neuropathic pain in breast cancer survivors, a new study shows. It included 240 women who” View full resource at drugs.com
Most Recently Shared on December 1, 2009 at 9:26 pm By:
Taxol Boosts Odds of Chronic Pain - http://bit.ly/6jWfGj
Taxol Linked to Neuropathic Pain in Women with Breast Cancer: Study - AboutLawsuits.com
aboutlawsuits.com — “Use of the chemotherapy drug Taxol (paclitaxel) may significantly increase the risk of chronic neuropathic pain in breast cancer survivors, according to a new” View full resource at aboutlawsuits.com
Most Recently Shared on December 9, 2009 at 2:32 pm By:
Women In Pain Health Organization
Taxol Linked to Neuropathic Pain in Women with Breast Cancer: Study - AboutLawsuits.com: http://bit.ly/5BLnnv via @addthis
A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal
hindawi.com — “The typically recommended chemotherapy options in metastatic anal cancer generally yield partial remissions with limited benefit for the majority of patients. TIP is a regimen containing paclitaxel (Taxol), ifosfamide, and cisplatin that is known to have significant activity in patients with squamous cell cancers of the head and neck as well as in cervical cancer, both of which are malignancies strongly associated with oncogenic strains of human papilloma virus (HPV). Interestingly, squamous cel” View full resource at hindawi.com
Most Recently Shared on June 17, 2011 at 1:15 am By:
A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal: The... http://bit.ly/moE4FC
Chemotherapy Drug Increases the Risk of Chronic Pain
spine-health.com — “Breast cancer survivors who received the chemotherapy drug paclitaxel (Taxol) are at an increased risk of developing chronic neuropathic pain, according to recent findings.” View full resource at spine-health.com
Most Recently Shared on December 16, 2009 at 9:00 pm By:
Chemotherapy Drug Increases the Risk of Chronic Pain http://bit.ly/92WhKf
Abraxis BioScience says data shows Abraxane works better than Taxol in lung cancer study - OrlandoSentinel.com
orlandosentinel.com — “NEW YORK (AP) — Abraxis BioScience said data from a late-stage study in lung cancer patients showed its drug Abraxane worked better than Taxol when given in combination with a chemotherapy drug.” View full resource at orlandosentinel.com
Most Recently Shared on June 7, 2010 at 7:15 pm By:
Abraxis BioScience says data shows Abraxane works better than Taxol in lung cancer study: NEW YORK (AP) — Abraxis ... http://bit.ly/cTa0jD
How Tumors Resist Chemotherapy: Scientific American
scientificamerican.com — “Studies spot a gene that allows some cancer cells to evade drugs such as Taxol.” View full resource at scientificamerican.com
Most Recently Shared on March 3, 2011 at 12:55 am By:
Scientific American Health Magazine
How Tumors Resist Chemotherapy http://bit.ly/hYoaFC
Medicinal tree used in chemotherapy drug faces extinction | Environment | The Guardian
guardian.co.uk — “Annual IUCN 'red list' of endangered species includes upgraded threat to tree whose bark is harvested for cancer treatment” View full resource at guardian.co.uk
Most Recently Shared on November 10, 2011 at 7:50 pm By:
Carlton Hoyt Science Enthusiast, PhD, and Doctor
Killing what cures you - the tree that produces the active ingredient in Taxol is almost extinct due to over-harvesting http://t.co/1kTOCeeG
Oncology News & Articles - MDLinx - Carboplatin Drug Therapy Radiotherapy Carcinoma on #MDlinx
mdlinx.com — “Oncology News & Articles - MDLinx - Carboplatin Drug Therapy Radiotherapy Carcinoma on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on July 27, 2010 at 7:53 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carbopla... http://bit.ly/bvyKDJ #oncology
Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy
medicalnewstoday.com — “Taxanes, a group of cancer drugs that includes paclitaxel (taxol®) and docetaxel (taxotere®), have become front-line therapy for a variety of metastatic cancers. but as with many chemother” View full resource at medicalnewstoday.com
Most Recently Shared on January 28, 2010 at 1:14 pm By:
Proteomics Study Reveals A Protein That, When Suppressed, Makes Cancers More Susceptible To Chemotherapy http://mnt.to/3wRc #cancer
HCPLive | The preeminent online destination for tools, techniques, and information for healthcare professionals | Oncology | Tissue Microarray Study Suggests Paclitaxel Improves Outcomes for Women with Basal Type Breast Cancer
hcplive.com — “In the quest to improve personalization of cancer treatment, the” View full resource at hcplive.com
Most Recently Shared on October 12, 2009 at 2:54 pm By:
RT @OncNetGuide #BreastCaSym Tissue Microarray Study Suggest Paclitaxel Improves Outcomes for Women http://tinyurl.com/yffa2kh
New Clinical Data Evaluating AVEO's Tivozanib in Combination with Paclitaxel to be Presented at 33rd Annual San Antonio Breast Cancer Symposium - Drugs.com MedNews
drugs.com — “Dec 2, 2010 - AVEO Pharmaceuticals, Inc. (NASDAQ AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics,” View full resource at drugs.com
Most Recently Shared on December 2, 2010 at 2:11 pm By:
Drugs and Devices OW OW Health
New Clinical Data Evaluating AVEO's Tivozanib in Combination with Paclitaxel to be Presented at 33rd Annua... http://bit.ly/g6NTp8 #drug
Life as a Healthcare CIO: Our Cancer Journey - Week 11
geekdoctor.blogspot.com — “Every day I experience life in the world of healthcare IT, supporting 3000 doctors, 18000 faculty, and 3 million patients. In this blog I record my experiences with infrastructure, applications, policies, management, and governance as well as muse on such topics such as reducing our carbon footprint, standardizing data in healthcare, and living life to its fullest.” View full resource at geekdoctor.blogspot.com
Most Recently Shared on March 1, 2012 at 11:08 am By:
John Halamka, MD Emergency Physician, Physician, and Doctor
Our Cancer Journey - Week 11: Tomorrow, Kathy starts her next round of chemotherapy - 12 weeks of Taxol administ... http://t.co/XFsDnB4k
ESMO: IPASS Data Show No Survival Benefit for Gefitinib (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “MILAN (MedPage Today) -- Final results of the IRESSA Ran Asia Study (IPASS) failed to show any difference in overall survival between patients with advanced non-small cell lung cancer treated with gefitinib (Iressa) or carboplatin (Paraplatin) and paclitaxel (Taxol) chemotherapy, researchers said here.” View full resource at qualitypointtech.net
Most Recently Shared on October 11, 2010 at 9:24 pm By:
ESMO: IPASS Data Show No Survival Benefit for Gefitinib (CME/CE): MILAN (MedPage Today) -- Final results of the IR... http://bit.ly/dCHVOt
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
msn
-
Timothy Lomauro
Timothy A. Lomauro, Ph.D. Clinical Psychologist and Psychology Professor, Allentown, Bethlehem, Philadelphia, and Wilkes-Barre
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
Advertisement
